SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

18 Jan 2020 Evaluate

Lupin has informed about press release titled ‘US FDA completes inspection of Lupin’s Vizag API facility’. Pharma major Lupin has announced the completion of an inspection carried out by the United States Food and Drug Administration (US FDA) at its Vizag API manufacturing facility. The inspection was carried out between January 13, 2020 and January 17, 2020. The inspection for the API facility at Vizag closed with five 483 observations.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2499.00 6.55 (0.26%)
07-Jul-2026 10:44 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1911.70
Dr. Reddys Labs. 1365.90
Cipla 1465.65
Zydus Lifesciences 1161.85
Lupin 2499.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: